Longevity Vision Fund
Longevity Vision Fund is a venture capital firm established in 2019 and based in New York. With a focus on making longevity affordable and accessible, the firm manages a $100 million investment fund dedicated to accelerating breakthroughs in extending healthy human lifespans. It invests in companies engaged in preventive medicine, early detection, medical technologies, artificial intelligence in healthcare, longevity therapies, regenerative medicine, and healthcare infrastructure. The fund provides financing from Seed to Series C stages for biotech and life extension-focused companies that exhibit the potential for affordable longevity solutions and a clear vision for achieving significant milestones and market validation. As a Registered Investment Adviser, Longevity Vision Fund aims to drive innovation in the longevity sector.
Juvenescence
Series B in 2019
Juvenescence Limited is a British Virgin Islands-based holding company focused on investing in the fields of human aging and longevity. The company aims to develop a comprehensive ecosystem of assets that target aging, age-related diseases, and regenerative medicine. By leveraging advancements in scientific and medical research, Juvenescence seeks to create therapeutics that significantly extend both healthspan and lifespan. Their approach involves forming partnerships with leading scientists and research institutions, in-licensing compounds from academia and industry, and developing novel therapies based on a deep understanding of the biological mechanisms of aging. Juvenescence's initiatives also encompass therapeutic strategies aimed at promoting healthy aging, metabolic health, and brain health, with the ultimate goal of addressing the societal implications of an aging population.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.